Abstract
Results
The differential expression of the 13 studied miRNAs in CD133+ cells separated from the HCC patients' peripheral blood compared to the controls revealed that miR-602, miR-181b, miR-101, miR-122, miR-192, miR-125a-5p , and miR-221 were significantly up regulated (fold change = 1.8, 1.7, 2, 5.4, 1.6, 2.9 & 1.5 P value = 0.039, 0.0019, 0.0013, 0.0370, 00024, 0.000044 &0.000007 respectively). As for the HCC group compared to the CHC group; miR-602, miR-122, miR-181b, miR-125a-5p, and miR-192 were significantly up regulated (fold change = 13, 3.1, 2.8, 1.6 & 1.56, P value = 0.01, 0.001, 0.000004, 0.002 & 0.007 respectively). Upon comparing the HCC group to the LC group; miR-199a-3p, miR-192, miR-122, miR-181b, miR-224, miR-125a-5p , and miR-885-5p were significantly up regulated (fold change = 5, 6.7, 2. CD133+ is a transmembrane glycoprotein that known as an important cell surface marker of the putative normal liver stem cells "oval cells" as well as cancer stem cells (CSCs) [3] [4] [5] [6] . In line with this, the increased expression of CD133+ was found to be correlated with advanced stages of HCC [7, 8] . A special attention is given to the naive circulating CD133+ cells and its clinical significance in HCC prognosis. We have previously showed that circulating CD133+ cells were significantly higher in the blood samples of chronic hepatitis and HCC patients compared to the healthy controls; revealing the prognostic role of CD133+ cells in those patients [9] .
MicroRNAs (miRNAs) are small, non-coding RNAs that can regulate carcinogenesis and cancer development through their complementary binding to mRNAs of oncogenes or tumor suppressors genes [10, 11] . miRNAs are involved in the regulation of proliferation and selfrenewal of the CSCs and they also promote the differentiation to determine the fate of stem cell [12] . Both normal stem cells (NSCs) and CSCs are regulated by miRNAs which accounts for the importance of the identifying the most common and unique miRNAs expression patterns between CSCs and NSCs.
The purpose of this study is to assess the expression patterns of 13 miRNAs in the naive circulating CD133+ stem cells associated with different stages of hepatocarcinogensis on top of HCV infection. Those miRNAs have been previously reported in literature to play a role in hepatocarcinogensis machinery. Also, this study is considered as a complementary study to our previously published paper which illustrated the expression pattern of those miRNAs in the serum samples of CHC, LC and HCC patients on top of HCV infection as well as healthy controls [13, 14] . and all were seronegative for HBV and HCV antibodies. The CHC and LC patients were diagnosed by clinical examination, abdominal ultrasound, laboratory investigations and liver biopsy. The diagnosis of HCC patients was based on computed tomography (CT) and elevated AFP level and confirmed by histopathology. The criteria for inclusion were as follows: a) adult patients of both sexes who were positive for HCV antibodies (EIAgen HCV Ab (v.4) kit code: 071064, adaltis. Milano Italy) as well as HCV RT-PCR (artus HCV RT-PCR Kits CE, cat no. 4518265, QIAGEN GmbH, QIAGEN Strasse 1, D-40724 Hilden); b) newly diagnosed HCC cases without prior chemotherapy. The criteria for exclusion were as follows: a) patients with positive hepatitis B surface antigen (HBsAg) and was confirmed by PCR; b) patients who received previous treatment for HCC. The study was approved by the Institutional Review Boards (IRB) of the National Cancer Institute, Cairo University, which was in accordance with the guidelines of 2004 Declaration of Helsinki. A written informed consent was obtained from all participants prior to enrollment in the study (Organization No.IORG0003381. IRB NO. IRB00004025).
Collection of clinical specimen
Ten milliliters of venous peripheral blood were collected from all enrolled subjects in CellSave blood collection tubes (Immunicon Inc., Huntingdon Valley, PA, United States) containing a cellular preservative and EDTA. Similarly, 10 ml of heparinized BM aspirate were collected from LC patients and normal volunteers during their regular treatment regimen and follow up. Briefly, patients' skin was cleaned with 70% ethanol at the iliac crest with a boring movement. Then, needles were passed perpendicularly into the cavity of the ileum at a point just posterior to anterior superior iliac spine or 2 cm posterior and 2 cm inferior to the anterior superior iliac spine to aspirate the BM (Salah and Klima New Delhi 110055, Delhi, India). The mononuclear cells were isolated from freshly collected peripheral blood and BM samples using RBC's lysis buffer. Cells were washed twice using phosphate buffer saline and counted using a hemocytometer.
CD133+ cells' sorting

CD133
+ cells were isolated using MACS kit (Miltenyi Biotec, Germany) according to manufacturer's instructions. The mononuclear cells were incubated for 30 min. at 4˚C after labeling with 100μl CD133/1 magnetic microbeads and 100 μl FcR. Then, the cells were sorted twice using the autoMACS™ separator (Miltenyi Biotec, GermanyF) to increase their purity. The cells were washed twice with phosphate buffered saline (pH 7.2); supplemented with 0.5% bovine serum albumin and 2mM EDTA, and centrifuged at 300 xg for 10 min at 4˚C. For confirmatory set, CD133+ cells were sorted using the BD FACSCalibur™ (BD Biosciences, USA) platform that allows performing both cell analysis and cell sorting in a single bench top system.
Flow cytometry analysis
The sorted cells were incubated with phycoerythrin (PE)-conjugated anti-CD133/2 for 30 min at 4˚C. (Miltenyi Biotec, Bergisch Gladbach, Germany). Then, they were treated with FcR blocking reagent (Miltenyi Biotec). The labeled cells were analyzed with Flowcytometer Epics1 Elite Coulter system using the CELL Quest software (Becton-Dickinson Immunocytometry Systems, San Jose, CA, USA). A nonspecific isotype control was used in each sample. All antibodies were of IgG1k isotype. Results were expressed as a specific percentage of positive markers, calculated by subtracting the nonspecific fluorescence of the isotype control form the specific fluorescence of the monoclonal antibody.
RNA extraction and cDNA synthesis
Total RNA including miRNA was extracted using RNeasy mini kit (Qiagen cat. no. 217004) and QIAzol lysis reagent according to manufacturer's instructions. The quality of the RNA was estimated using 2000\2000c nanodrop (Thermo scientific, USA). RT2 miRNA First Strand Kit (Qiagen) was used to prepare cDNA from 500 ng RNA. Reverse transcription was carried out in a final reaction volume of 20 μl that were incubated for 60 min at 37˚C followed by 5 min at 95˚C.
Quantitative real-time PCR
The relative expression levels of 13 mature miRNAs [hsa-miR-122, hsa-miR-192, hsa-miR-885-5p, hsa-miR-375, hsa-miR-224, hsa-221, hsa-miR-22, hsa-miR-101, hsa-miR-602, hsamiR-125a-5p, hsa-miR-181b, and hsa-miR-199a-3p] in CD133 cells were performed using miScript miRNA PCR custom array (SABiosciences, custom array catalog number caih0038). For real time PCR, the reaction mixture contained 13 μl SYBR PCR master mix and 2 μl diluted cDNA (1:10) in a final volume of 25 μl for each miRNA. The amplification step was carried out for 40 cycles according to the following conditions: 95˚C for 10 minutes, 1 cycle; 95˚C for 15 seconds, 60˚C for 40 seconds, 72˚C for 30 seconds. The 13 miRNAs were compared and analyzed across multiple plates using the ΔΔCt method and normalized to snord48 (housekeeping gene).
miRNAs selection and target prediction
The selection of the miRNAs was based on a previous review of literature along with using miR2Disease database; a comprehensive resource of miRNA deregulation in various human diseases (http://www.mir2disease.org). While, miRTaBase database; the experimentally validated miRNA-target interaction database (mirtarbase.mbc.nctu.edu.tw) was used to predict downstream targets of miRNAs.
Confirmatory reverse transcription and Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR)
CD133 cells were sorted from blood samples obtained from eight HCC patients and eight control subjects using flowcytometry with cell sorter. Total RNA was reverse transcribed for sorted CD133 cells using miScript II RT kit (Qiagen). Reactions were incubated at 37˚C for 1 hr followed by inactivation of the reaction by incubation at 95˚C for 10 min. For miRNA expression Confirmatory Real-time PCR was carried out for the four miRNAs (miRNA-122, miRNA181b, miRNA-125a-5p, miRNA-192) using primers specific for these miRNAs, Table 1 , 1 μL of diluted RT product was used (equivalent to 3 ng) as template in a 10 μL PCR reaction containing 1X SYBR Green master mix (Qiagen), 200nMmiRNA specific forward primer, and 200 nM universal primer. The conditions for qRT-PCR were as follows: 95˚C for 10min, followed by 40 cycles of 95˚C for 15s and 50˚C for 30 s and 70˚C for 30 s. All the RT-qPCR reactions were performed on 7500 fast real-time PCR system (Applied Biosystems). All samples were analysed in duplicate.
Statistical analysis
Data analysis was performed using the supplied software "http://www. 
Results
The demographic features and the clinical data of the studied groups
The demographic and the clinical features of the different studied groups were shown in Table 2 . The age differed significantly between the studied groups (P value < 0.05) with a trend for increasing ages with disease progression. However, there was no significant difference between the LC and the HCC groups regarding the age. Also, no significant difference was observed regarding the gender between the studied groups with male predominance in the groups with HCV-related liver disease except for those in the CHC group. The level of AST was significantly higher in the LC and CHC groups compared to the other groups (P value < 0.05). However, levels of total bilirubin and AST were significantly higher in the LC group compared to the other groups (P value < 0.05, 0.01 respectively). Albumin was significantly lower in the LC group compared to the other groups (P value < 0.05) whereas; AFP was significantly higher in the HCC group compared to the other groups (P value < 0.01).
CD133+ subpopulation purity in the different studied groups
Prior to performing the custom miScript miRNA PCR array, the purity of sorted CD133+ cells was tested in all studied groups by flowcytometry. The purity of CD133+ subpopulation ranged from 67 to 76% in the different studied groups as shown in Fig 1. The differential expression of miRNAs in CD133+ cells purified from the peripheral blood (PB) of the different studied groups Among the 13 studied miRNAs, only miR-101 was significantly up regulated (fold change = 1.69 P value = 0.016) while miR-122 was significantly down regulated (fold change = -1.74 P value = 0.0114) upon comparing CD133+ cells of the CHC group to those of the control group as shown in S1 The heat map with dendograms for the differential expression of 13 miRNAs in CD133+ cells of the three studied groups compared to the control group indicates co-regulated miRNAs across all studied groups along with multi group plot provided both a bar chart and line graph representation (with optional error bars) are shown in The histograms representing the differential expression of miRNAs in CD133+ cells purified from peripheral blood of all studied groups were shown in Fig 5. The possible mechanistic role of significant overlapping miRNAs in CD133+ cells of HCC with their downstream targets as well as the relationship between miRNAs and HCV were illustrated in Table 3 The histograms representing the differential expression of miRNAs in CD133+ cells purified from bone marrow of the LC and control groups were shown in Fig 8. 
Confirmatory set results
The differential expression of the studied miRNAs in CD133+ of the HCC group compared to the control group showed up regulation of miR-181b, miR-192, miR-125a-5p and miR-122 in concordance with the our previous data Table 4 , Fig 9. Moreover, there is no significant difference in the miRNA expression between both methods used for CD133+ cell sorting. 
Discussion
Cancer stem cells (CSCs) represent a subset of cells that exist within the tumor. They are responsible for resistance, survival and recurrence after the treatment. CD133+ has drawn a significant attention as a critical liver CSC marker [15] . There is evidence that miRNAs are significantly involved in self-renewal and differentiation of CSCs [16] . They are responsible for regulating the stemness characteristics through modulation of tumor-suppressive and oncogenic pathways [17] .
In this study, we aimed to differeniate between the naive circulating CD133 + cells obtained from patients at different stages of HCV-associated liver disease and the CD133 + cells of the healthy controls at the molecular level through comparing the expression patterns of 13 miRNAs.
Our
results revealed that miR-181b, miR-602, miR-101, miR-122, miR-192, miR-125a-5p miR-221 and miR-22
were significantly up regulated up on comparing CD133+ cells of the HCC group (PB) to those of the control group (PB). MiR-181b which belongs to miR-181s family; plays an important role in liver injury and cancer development [18] . Significant up regulation of miR-181b was in concordance with a previous report by Ji et al. who found that multiple members of the miR-181 family, including miR-181b are up-regulated in the liver CSC subset marked with EpCAM+ AFP+ [19] . Similarly, our previous study addressed that miR-181 was significantly up regulated in sera of the HCC group when compared to the LC group [14]. Moreover, Meng et al identified the differential expression of miR-181 family members in an Oct4 + CD133 + liver CSC subset. They also identified a critical role for miR-181s in Twist-driven metastasis in this Oct4 liver CSCs through targeting RAS-association domain family 1, isoform A (RASSF1A), tissue inhibitor of metalloproteinase 3 (TIMP3) and nemo-like kinase (NLK) [18] . Furthermore, miR-181s was found to maintain stemness by directly targeting GATA-binding protein 6 (GATA6) caudal type homeobox 2 (CDX2) and nemo-like kinase (NLK) which is a potent inhibitor of β-catenin resulting in activation of the Wnt/β-catenin pathway in EpCAM + liver CSCs [19] .
Our data regarding the significant up regulation of miR-602 was in agreement with yang et al. who identified the oncogenic function of miR-602 in HCC through targeting the tumor suppressive function of RASSF1A [20] . On the other hand, miR-101 was reported to inhibit tumor aggressiveness through targeting EZH2 which is an epigenetic regulator of cell survival, proliferation, CSC phenotype and function, in various cancers including endometrial cancer Additionally, miR-125a is frequently down-regulated in HCC and it inversely correlated with aggressiveness and poor prognosis of the tumor. Ectopic expression of miR-125a may down-regulate MMP11 and VEGF in vitro and in vivo supporting its role as tumor suppressive miRNA; inhibiting the proliferation, invasion and metastasis of HCC [38] . Moreover, miR125a inhibits the invasion of HCC cells through regulating the PI3K/AKT/mTOR pathway [39] . However, the significant up-regulation of miR-125a-5p in this study came in agreement CCNG1 p53 and p73 activate the CCNG1 during the transcription steps that in turn suppress p53 family proteins leading to cell survival activation.
miR-192
SEMA3A Inhibits the Rac-PAK pathway responsible for regulation of actin dynamics; resulting in cytoskeleton remodeling.
miR-181b
TIMP3 Exerts its anti-angiogenic effect via a direct interaction with vascular endothelial growth factor (VEGF) receptor-2 resulting in inhibition of proliferation, migration and tube formation of endothelial cells (ECs).
GATA6
The transcription factor GATA6 directly regulates expression of leucine-rich repeat containing G protein-coupled receptor 5 (LGR5) involved in the differentiation pathway.
CDX2 CDX2 is (caudal type homeobox 2) is an important transcription factor in the differentiation pathway
NLK
Inhibits of wnt/β-catenin signaling
miR-125a-5p
BAK-1 Involved in S6K1-BAD-BAK apoptotic pathway
P53
Involved in P53 apoptotic pathway
EBBR2/3 Involved in cytoskeleton remodeling
https://doi.org/10.1371/journal.pone.0193709.t003
with an early report by Guo et al. who proved that miR-125a alone was capable of increasing the number of hematopoietic stem cells in vivo via targeting multiple proapoptotic genes e.g. Bak1 [40] . In addition, ERBB2 and ERBB3 were negatively regulated by miR-125a and miR125b. In CD133+ cells, the down-regulation of ERBB2 due to the effect of miR-125 might lead to more polarized morphology. Therefore, miR-125a plays an anti apoptotic role and participates in remodeling of cytoskeleton and dedifferentiation [41] . miR-221 is up regulated in 70%-80% of HCC samples with the maximum divergence affecting several cancer pathways [42] . Also, miR-221 stimulates the onset of tumors, promotes tumor progression and shorts the time to death in the mouse model of liver cancer [43] . miR- . We have previously reported a similar data regarding the up regulation of miR-221 in HCC patients`sera compared to LC patients. Upon comparing CD133+ cells of the HCC group (PB) to CD133+ cells of the CHC group (PB); miR-181b, miR-122, miR-192 and miR-125a-5p were significantly up-regulated. Furthermore, miR-122, miR-192, miR-125a-5p and miR-181b were significantly common up-regulated miRNAs in CD133+ cells of the HCC group (malignant group) compared to the other nonmalignant groups (CHC, LC and control groups).
To the best of our knowledge, this the first study showed the differential miRNAs expression pattern of CD133+ cells obtained from BM versus CD133+ cells obtained from PB of the same participant. We found that miR-122, miR-221 and miR-125a-5p were significantly up- regulated on comparing CD133+ cells separated from BM to those separated from PB of the control group. However, miR-885-5p, miR-224 and miR-199a-3p were significantly up-regulated whereas miR-22, miR-101 and miR-29b were significantly down-regulated in the CD133 + cells separated from BM compared to those separated from PB of the LC group. On comparing the differential miRNAs expression pattern of CD133+ cells separated from BM of the LC group to those separated from BM of the control group vs. CD133+ cells separated from PB of the LC group to those separated from PB of the control group we found that miR-122, miR-192, miR-199a-3p , miR-125a-5p and miR-224 were common significantly down regulated miRNAs. Further study will be needed to investigate the role of those miRNAs in the differentiation of CD133+ cells.
Conclusion
These results have provided the evidence that the miRNAs differentially expressed between the CD133+ cells associated with HCC group associated with HCV infection and CD133+ cells of the other non-malignant studied groups. Those miRNAs are highly involved in stemness, proliferation, and remodeling of cytoskeleton and apoptosis blocking. These findings broaden our knowledge about the molecular characterization along with phenotypic characterization of CD133+ cells for stem cell-based therapies. However, there are some limitations in this study as phenotypic characterization with the double stained and clonogenic assays will be needed to prove the carcinogenic properties of the stem cells harboring CD133+ surface marker in HCC. 
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